The Latest Breaking News from FDA

In the swiftly progressing arena of biotechnology, technological advancements, increasing merger and acquisition maneuvers, and developing product pipelines are driving significant expansion in this sector. The sector's strong potential is further reinforced by a steady demand, ensuring its sustenance. Given this backdrop, let’s analyze whether or not biotech stocks Illumina…

A slew of features will be rolling out this morning for Pixel users as part of the January 2024 feature drop. This includes a fully realized temperature sensor, Magic Compose, and more.

The biotech industry is well poised to flourish, buoyed by its commitment to innovation and potential for groundbreaking discoveries. Thus, investing in the shares of three fundamentally solid biotech companies, Foghorn Therapeutics (FHTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD), might be prudent. Continue reading….

A new study suggests a promising blood test that could diagnose Alzheimer's disease accurately and early, potentially revolutionizing dementia care.

Top-notch biotech stock Pharvaris surged Monday after the FDA said it could begin testing a treatment for a swelling disorder in people.

They're pioneering a new model of care that will allow for one-stop, same-day access to mifepristone — no appointment necessary.

ARK Innovation, the flagship Cathie Wood ETF, is skidding in 2024 as the S&P 500 hits a record high. Blame Coinbase, Tesla and other big ARKK ETF holdings.

This informative article discusses the push to ban menthol cigarettes and its potential impact on public health, particularly in black communities.

The Checks and Balances Letter delivers news and information from Ballotpedia’s Administrative State Project, including pivotal actions at the federal and state levels related to the separation of powers, due process, and the rule of law.

The White House just released a proposal that would allow federal agencies to rip up patent licensing agreements between universities -- which may receive federal research funds -- and private companies, including biotech firms.

Bovine colostrum supplements are taking over, but the evidence for some claims is lacking